Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets ...Middle East

SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery...

Hence then, the article about huadong medicine and insilico medicine enter co development partnership to advance oncology drug discovery by hitting undruggable targets was published today ( Wednesday 08/09/2021 - 02:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets )

Also on site :

• Claroty Secures $150 Million in Series F Funding to Lead Charge on Securing the World's Mission Critical Infrastructure
• Immfly to bring Eutelsat's OneWeb LEO High-Speed connectivity to disconnected narrowbody LCC/ULCC fleets worldwide
• Microsoft and Mercedes-AMG PETRONAS F1 Team unite to drive innovation from factory to circuit